Anika Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0352551081
USD
9.49
0.06 (0.64%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Anika Therapeutics, Inc. stock-summary
stock-summary
Anika Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Anika Therapeutics, Inc. is a joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care. It partners with physicians and develops minimally invasive products. It focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. Its product categories include joint pain management therapies, orthopedic joint preservation and restoration care, and other. The joint pain management therapies offer injectable viscosupplement products that provide pain relief from osteoarthritis conditions and its products include MONOVISC, ORTHOVISC, CINGAL and HYVISC. The Company's orthopedic joint preservation and restoration care products include HYALOFAST and TACTOSET. It also offers a line of surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons due to sports injuries, trauma and disease.
Company Coordinates stock-summary
Company Details
32 Wiggins Ave , BEDFORD MA : 01730-2315
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 46 Schemes (35.68%)

Foreign Institutions

Held by 61 Foreign Institutions (5.8%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Joseph Bower
Independent Chairman of the Board
Dr. Cheryl Blanchard
President, Chief Executive Officer, Director
Mr. John Henneman
Independent Director
Mr. Raymond Land
Independent Director
Dr. Glenn Larsen
Independent Director
Mr. Stephen Richard
Independent Director
Mr. Jeffery Thompson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
28 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 129 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.35

stock-summary
Return on Equity

-25.67%

stock-summary
Price to Book

0.87